Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.

You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-DNA-PK-ZL-2201 mesylate
ZL-2201 mesylate

Chemical Structure : ZL-2201 mesylate

CAS No.: 2865115-39-3

ZL-2201 mesylate (ZL2201 mesylate)

Catalog No.: PC-21129Not For Human Use, Lab Use Only.

ZL-2201 mesylate (ZL2201) is a highly potent, selective and orally bioavailable inhibitor of DNA-dependent protein kinase (DNA-PK) with IC50 of 1.1 nM.

Packing Price Stock Quantity
50 mg Get quote
100 mg Get quote
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

ZL-2201 mesylate (ZL2201) is a highly potent, selective and orally bioavailable inhibitor of DNA-dependent protein kinase (DNA-PK) with IC50 of 1.1 nM.
ZL-2201 shows no significant activities against human mTOR, ATM, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ PI3-kinases (all IC50 >1000 nM).
ZL-2201 exhibits antiproliferative activity against ATM-deficient NSCLC cell lines (H1373, H23, H522, H1395, H1703) with IC50 of 3.98-12.2 uM, selectively inhibits DNA-PK autophosphorylation at Ser2056.
ZL-2201 robustly inhibits NHEJ-mediated repair of exogenous DNA damage resulting in increased G2–M arrest and apoptosis in vitro.
ZL-2201 (60 mg/kg) inhibits DNA-PK autophosphorylation and exhibits potent antitumor efficacy in vivo of NCI-H1703 xenografts.
ZL-2201 could synergy with various DNA-damaging agents, significantly augments antitumor activity of DSB-inducing agents doxorubicin and IR.

Physicochemical Properties

M.Wt 503.54
Formula C20H25N9O5S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

8H-Purin-8-one, 7,9-dihydro-7-methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-, methanesulfonate (1:1)

References

1. Shruti Lal, et al. Cancer Res Commun. 2023 Sep 1;3(9):1731-1742.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: